Alaunos Therapeutics (TCRT) Registration filing summary

Company overview and business model

• Biopharma pipeline targets pulmonary arterial hypertension (PAH) and related cardiopulmonary disease; VLR199 is an activin receptor type IIA-Fc ligand trap.

• VLR247 and VLR258 are designed to spare BMP9/10; VLR360 targets platelet-derived growth factor B; ALN1003 is a preclinical oral obesity and metabolic disease candidate.

• Research programs with Paragon cover ActRIIA, ActRIIB and BMP9/10-sparing ActRIIA fusion proteins; license options remain unexercised.

• VLR199 IND or CTA submission is targeted for H2 2027, with initial Phase 1 proof-of-concept data anticipated in 2028.

Financial performance and metrics

• PIPE closed October 14, 2026, raising approximately $350.0m through common stock and Series C preferred stock sold at $1.4357 per common-equivalent share.

• Velaris recorded $18.5m of Paragon-related expense through October 13, 2026: $17.9m R&D and $0.6m G&A; $13.4m had been paid as of the prospectus date.

• Cherry Bekaert’s audit report on FY2025 financial statements included an explanatory paragraph regarding ability to continue as a going concern.

Use of proceeds and capital allocation

• Selling stockholders receive all resale proceeds; no proceeds from these sales accrue to the issuer.

• Registration costs are borne by the issuer; selling holders generally pay their own brokerage, accounting, tax and legal disposal expenses.

• Paragon arrangements include $18.5m of pre-effective-date development costs, up to $62.5m in milestone payments per product, high-single-digit royalties under future licenses and two warrants each for 1% of fully diluted shares.